Palvella Therapeutics Reports 2025 Results

Palvella Therapeutics has announced its full-year 2025 financial results and provided a corporate update, confirming that its New Drug Application (NDA) for QTORIN™ rapamycin is on track for submission. The drug is intended for the treatment of microcystic lymphatic malformations. This update signifies progress in the company's drug development pipeline and regulatory efforts. The planned submission marks a key milestone for Palvella Therapeutics as it moves towards potential market approval for its novel therapeutic candidate.